Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer

Lung cancer causes more than 1.7 million deaths worldwide each year, with NSCLC accounting for about 85 percent of all cases[1] The cobas EGFR Mutation Test v2 is FDA approved as a companion diagnostic for the detection of EGFR mutations in NSCLC for bo... Diagnostics, Oncology, FDA Roche Group, cobas, EGFR Mutation Test, NSCLC, lung cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news